When administered at the onset of HAE
attack symptoms at the recommended dose, RUCONEST works to return a patient's C1-INH levels to normal range and quickly begins to relieve the symptoms of an HAE
attack with a low recurrence of symptoms.
While a very small number of people use HAE
drugs, the increased use and costs call for high touch case management as an essential HAE
FIRAZYR is currently approved in 38 countries worldwide, including the countries of the European Union and the United States for the treatment of acute attacks of HAE
Overwhelming evidence suggests that the symptoms of HAE
are mainly the result of a deficiency in the regulation ofthelatter pathway.
often involves constant low-grade spontaneous activation of complement, C4 can also be low when patients are asymptomatic.
treatment of HAE
, a rare hereditary condition characterized by episodes of acute swelling and inflammation that can peripherally affect the extremities (hands, feet, face), the abdominal tract, the genitalia, and in life- threatening cases, the larynx.
In 255 HAE
patients treated with intravenous or subcutaneous KALBITOR in clinical studies, 10 patients (3.
Safety and Efficacy of Recombinant Human C1 inhibitor for the Treatment of HAE
Attacks in Pediatric Patients- Oral Presentation by Dr.
We re excited to offer the only recombinant C1 esterase inhibitor therapy for HAE
in the United States, said Carolyn J.
May 14, 2014 /PRNewswire/ -- As a Diamond Sponsor of HAE
Day on May 16, 2014, CSL Behring is proud to continue its partnership with HAEi, the International Patient Organization for C1 Inhibitor Deficiencies, and patient organizations throughout the world.
The study showed that patients receiving treatment with FIRAZYR experienced a significantly faster time to onset of symptom relief from individual and combined cutaneous and abdominal HAE
symptoms, compared to those receiving placebo.
Monitor Helps Patients and Physicians More Effectively Track HAE
Symptoms and Improve Treatment Decisions